1040 related articles for article (PubMed ID: 24582013)
1. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
2. Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Otto S; Pautke C
J Oral Maxillofac Surg; 2014 May; 72(5):903-10. PubMed ID: 24485975
[TBL] [Abstract][Full Text] [Related]
3. Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Ristow M; Koerdt S; Schuster R; Otto S; Pautke C
J Cancer Res Clin Oncol; 2014 Mar; 140(3):487-93. PubMed ID: 24469255
[TBL] [Abstract][Full Text] [Related]
4. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
5. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
7. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
O'Halloran M; Boyd NM; Smith A
Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835
[TBL] [Abstract][Full Text] [Related]
8. Review of current literature and implications of RANKL inhibitors for oral health care providers.
Epstein MS; Ephros HD; Epstein JB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640
[TBL] [Abstract][Full Text] [Related]
9. The effects of bisphosphonate on the remodeling of different irregular bones in mice.
Su J; Feng M; Han W; Zhao H
J Oral Pathol Med; 2015 Sep; 44(8):638-48. PubMed ID: 25370709
[TBL] [Abstract][Full Text] [Related]
10. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
de Molon RS; Shimamoto H; Bezouglaia O; Pirih FQ; Dry SM; Kostenuik P; Boyce RW; Dwyer D; Aghaloo TL; Tetradis S
J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
[TBL] [Abstract][Full Text] [Related]
11. Infection and medication-related osteonecrosis of the jaw.
Katsarelis H; Shah NP; Dhariwal DK; Pazianas M
J Dent Res; 2015 Apr; 94(4):534-9. PubMed ID: 25710950
[TBL] [Abstract][Full Text] [Related]
12. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
13. Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.
Wehrhan F; Hyckel P; Amann K; Ries J; Stockmann P; Schlegel K; Neukam F; Nkenke E
Oral Dis; 2011 May; 17(4):433-42. PubMed ID: 21366807
[TBL] [Abstract][Full Text] [Related]
14. Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis.
Aoki K; Matsunaga S; Ito S; Shibahara T; Nomura T; Matsuzaki H; Abe S; Yamaguchi A
J Bone Miner Metab; 2021 Sep; 39(5):737-747. PubMed ID: 33830351
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
Rachner TD; Platzbecker U; Felsenberg D; Hofbauer LC
Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
[TBL] [Abstract][Full Text] [Related]
16. Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases.
Yuan A; Munz A; Reinert S; Hoefert S
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Feb; 129(2):133-140. PubMed ID: 31606424
[TBL] [Abstract][Full Text] [Related]
17. Intraindividual comparison of preoperative (99m)Tc-MDP SPECT/CT and intraoperative and histopathological findings in patients with bisphosphonate- or denosumab-related osteonecrosis of the jaw.
Assaf AT; Zrnc TA; Remus CC; Adam G; Zustin J; Heiland M; Friedrich RE; Derlin T
J Craniomaxillofac Surg; 2015 Oct; 43(8):1461-9. PubMed ID: 26232916
[TBL] [Abstract][Full Text] [Related]
18. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
[TBL] [Abstract][Full Text] [Related]
19. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S; Lumachi F; Stellini E; Favero L
Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
[TBL] [Abstract][Full Text] [Related]
20. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
You Tm; Lee KH; Lee SH; Park W
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
